SARS-CoV-2 Doggybone DNA Vaccine Produces Cross-Variant Neutralizing Antibodies and Is Protective in a COVID-19 Animal Model

To combat the COVID-19 pandemic, an assortment of vaccines has been developed. Nucleic acid vaccines have the advantage of rapid production, as they only require a viral antigen sequence and can readily be modified to detected viral mutations. Doggybone™ DNA vaccines targeting the spike protein of S...

Descripción completa

Detalles Bibliográficos
Autores principales: Mucker, Eric M., Brocato, Rebecca L., Principe, Lucia M., Kim, Robert K., Zeng, Xiankun, Smith, Jeffrey M., Kwilas, Steven A., Kim, Sungwon, Horton, Helen, Caproni, Lisa, Hooper, Jay W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9317096/
https://www.ncbi.nlm.nih.gov/pubmed/35891268
http://dx.doi.org/10.3390/vaccines10071104

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9317096/
https://www.ncbi.nlm.nih.gov/pubmed/35891268
http://dx.doi.org/10.3390/vaccines10071104

Ejemplares similares